Inna Chen

Medicine & Life Sciences

1. Pancreatic Neoplasms 100%
2. Adenocarcinoma 81%
3. Survival 54%
4. Biomarkers 47%
5. Biliary Tract Neoplasms 38%
6. Interleukin-6 26%
7. Serum 24%
8. Neoplasms 21%
9. Ipilimumab 21%
10. Collagen 20%
11. Nivolumab 20%
12. Collagen Type III 19%
13. tocilizumab 18%
14. gemcitabine 17%
15. Fibrosis 17%
16. Proteins 15%
17. Radiosurgery 14%
18. Colitis 13%
19. Carbohydrates 13%
20. Fibrillar Collagens 12%
21. oligochitosan 12%
22. C-Reactive Protein 12%
23. Combination Drug Therapy 11%
24. Therapeutics 11%
25. Collagen Type XI 11%
26. Colorectal Neoplasms 11%
27. Lung Neoplasms 11%
28. Cancer-Associated Fibroblasts 10%
29. Circulating Tumor DNA 10%
30. Drug Therapy 10%
31. Tumor Biomarkers 10%
32. 130-nm albumin-bound paclitaxel 10%
33. Plasma Kallikrein 10%
34. Collagen Type V 9%
35. Confidence Intervals 9%
36. Tumor Microenvironment 9%
37. Randomized Controlled Trials 9%
38. Cohort Studies 9%
39. Antigens 9%
40. Exercise 8%
41. Interleukin-15 8%
42. Capecitabine 8%
43. Vitamin D Deficiency 7%
44. Patient Participation 7%
45. Transforming Growth Factors 6%
46. Hyaluronic Acid 6%
47. Mortality 6%
48. Life Expectancy 6%
49. Diarrhea 6%
50. Counseling 6%